Lucentis (Ranibizumab) in Diabetic Macular Oedema: a Treatment Evaluation

PHASE4CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

October 31, 2010

Primary Completion Date

July 31, 2012

Study Completion Date

July 31, 2012

Conditions
Diabetic Retinopathy
Interventions
DRUG

Ranibizumab

Intravitreal injection of 0.5mg in 0.05ml. One injection at baseline, 4 and 8 weeks then four-weekly as required to 44 weeks.

PROCEDURE

Modified ETDRS laser

Argon laser therapy to the macula in accordance with the modified ETDRS protocol at baseline, 12, 24 and 36 weeks.

Trial Locations (1)

EC1V 2PD

Moorfields Eye Hospital, London

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

Moorfields Eye Hospital NHS Foundation Trust

OTHER